Time and time again: Temporal processing demands implicate perceptual and gating deficits in the HIV-1 transgenic rat

Journal of Neuroimmune Pharmacology

Volumn 8, Issue 4, 2013, Pages 988-997

  Moran, Landhing M ^a   Booze, Rosemarie M ^a   Mactutus, Charles F ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

AIDS; HIV 1 transgenic rat; HIV 1 associated neurocognitive disorders; Perceptual sharpening; Prepulse inhibition; Sensorimotor gating

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUDITORY RESPONSE; CONTROLLED STUDY; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; HIV ASSOCIATED DEMENTIA; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; NEUROLOGIC DISEASE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SENSORY GATING; STARTLE REFLEX; STIMULUS; TRANSGENIC RAT;

ACOUSTIC STIMULATION; ANIMALS; AUDITORY PERCEPTION; FEMALE; HIV-1; PHOTIC STIMULATION; RATS; RATS, INBRED F344; RATS, TRANSGENIC; SENSORY GATING; TIME FACTORS; VISUAL PERCEPTION;

EID: 84882277186     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-013-9472-6     Document Type: Article

References (63)

1. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R (1982) Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 17:639-654
2. Aksenov MY, Aksenova MV, Silvers JM, Mactutus CF, Booze RM (2008) Different effects of selective dopamine uptake inhibitors, GBR 12909 and WIN 35428, on HIV-1 Tat toxicity in rat fetal midbrain neurons. Neurotoxicology 29:971-977
3. Aksenova MV, Silvers JM, Aksenov MY, Nath A, Ray PD, Mactutus CF, Booze RM (2006) HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci Lett 395:235-239
4. Ances BM, Ellis RJ (2007) Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 27:86-92
5. Bankaitis AE (1995) The effects of click rate on the auditory brain stem response (ABR) in patients with varying degrees of HIV-infection: a pilot study. Ear Hear 16:321-324
6. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L (1978) Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 15:339-343
7. Campbell BA, Haroutunian V (1983) Perceptual sharpening in the developing rat. J Comp Psychol 97:3-11
8. Castello E, Baroni N, Pallestrini E (1998) Neurotological and auditory brain stem response findings in human immunodeficiency virus-positive patients without neurologic manifestations. Ann Otol Rhinol Laryngol 107:1054-1060
9. Chang L, Wang GJ, Volkow ND, Ernst T, Telang F, Logan J, Fowler JS (2008) Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. NeuroImage 42:869-878
10. Chao LL, Lindgren JA, Flenniken DL, Weiner MW (2004) ERP evidence of impaired central nervous system function in virally suppressed HIV patients on antiretroviral therapy. Clin Neurophysiol 115:1583-1591
11. di Rocco A, Bottiglieri T, Dorfman D, Werner P, Morrison C, Simpson D (2000) Decreased homovanilic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin Neuropharmacol 23:190-194
12. Ellis RJ, Deutsch R, Heaton RK, Marcotte TD, McCutchan JA, Nelson JA, Abramson I, Thal LJ, Atkinson JH, Wallace MR, Grant I (1997) Neurocognitive impairment is an independent risk factor for death in HIV infection. Arch Neurol 54:416-424
13. Fein G, Biggins CA, Mackay S (1995) Delayed latency of the event-related brain potential P3A component in HIV disease: progressive effects with increasing cognitive impairment. Arch Neurol 52:1109-1118
14. Ferris MJ, Frederick-Duus D, Fadel J, Mactutus CF, Booze RM (2009) The human immunodeficiency virus-1-associated protein, Tat(1-86), impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study. Neuroscience 159:1292-1299
15. Fitting S, Booze RM, Mactutus CF (2006a) Neonatal hippocampal Tat injections: developmental effects on prepulse inhibition (PPI) of the auditory startle response. Int J Dev Neurosci 24:275-283
16. Fitting S, Booze RM, Mactutus CF (2006b) Neonatal intrahippocampal glycoprotein 120 injection: the role of dopaminergic alterations in prepulse inhibition in adult rats. J Pharmacol Exp Ther 318:1352-1358
17. Frank Y, Pahwa S (1993) Serial brain-stem auditory-evoked responses in infants and children with AIDS. Clin Electroencephalogr 24:160-165
18. Frank Y, Vishnubhakat SM, Pahwa S (1992) Brain stem auditory evoked-responses in infants and children with AIDS. Pediatr Neurol 8:262-266
19. Ganz L (1968) An analysis of generalization behavior in the stimulus deprived organism. In: Newton G, Levine S (eds) Early experience and behavior: The psychobiology of development. Charles C. Thomas, Springfield, pp 365-411
20. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154
21. Gibson EJ (1969) Principles of perceptual learning and development. Appleton, New York
22. Gil R, Breux JP, Neu JP, Becq-Giraudon B (1992) Cognitive evoked potentials and HIV infection. Neurophysiol Clin 22:385-391
23. Golob EJ, Irimajiri R, Starr A (2007) Auditory cortical activity in amnestic mild cognitive impairment: relationship to subtype and conversion to dementia. Brain 130:740-752
24. Goodwin GM, Pretsell DO, Chiswick A, Egan V, Brettle RP (1996) The Edinburgh cohort of HIV-positive injecting drug users at 10 years after infection: a case-control study of the evolution of dementia. AIDS 10:431-440
25. Gottlieb G (1971) Ontogenesis of sensory function in birds and mammals. In: Tobach E, Aronson LR, Shaw E (eds) The biopsychology of development. Academic, New York, pp 67-128
26. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F et al (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER study. Neurology 75:2087-2096
27. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S et al (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3-16
28. Hoffman HS, Ison JR (1980) Reflex modification in the domain of startle: I. Some empirical findings and their implications for how the nervous system processes sensory input. Psychol Rev 87:175-189
29. Hoffman HS, Searle JL (1965) Acoustic variables in modification of startle reaction in rat. J Comp Physiol Psychol 60:53-58
30. Hord LL, Booze RM, Mactutus CF (2008) Ontogeny of prepulse inhibition of the acoustic startle response across modality. Abstracts: International Society for Developmental Psychobiology, 41st annual meeting, November 12-15, 2008 Washington D.C. Dev Psychobiol 50:720-750
31. Ison JR, Hammond GR (1971) Modification of startle reflex in rat by changes in auditory and visual environments. J Comp Physiol Psychol 75:435-452
32. Kerr LM, Ostapoff EM, Rubel EW (1979) Influence of acoustic experience on the ontogeny of frequency generalization gradients in the chicken. J Exp Psychol Anim Behav Process 5:97-115
33. Koralnik IJ, Beaumanoir A, Hausler R, Kohler A, Safran AB, Delacoux R et al (1990) A controlled-study of early neurologic abnormalities in men with asymptomatic human-immunodeficiency-virus infection. N Engl J Med 323:864-870
34. Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M (2011) Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. J Neurovirol 17:26-40
35. Lalwani AK, Sooy CD (1992) Otologic and neurotologic manifestations of acquired-immunodeficiency-syndrome. Otolaryngol Clin North Am 25:1183-1197
36. Matas CG, Silva SM, Marcon Bde A, Goncalves IC (2010) Electrophysiological manifestations in adults with HIV/AIDS submitted and not submitted to antiretroviral therapy. Pro Fono 22:107-113
37. Midde NM, Huang X, Gomez AM, Booze RM, Zhan CG, Zhu J (2013). Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions. J Neuroimmune Pharmacol
38. Moran LM, Aksenov MY, Booze RM, Webb KM, Mactutus CF (2012) Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge. Curr HIV Res 10:415-424
39. Moran LM, Booze RM, Webb KM, Mactutus CF (2013) Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction. Exp Neurol 239:139-147
40. Moran LM, Mactutus CF, Booze RM (2009) Generality of disruption of prepulse inhibition by the dopamine agonist apomorphine. http://www.cpdd.vcu. edu/Pages/Meetings/CPDD09AbstractBook.pdf Accessed 01 May 2013.
41. Mozes MM, Bryant JL, Franks R, Chan CC, Kopp JB (2002) Congenital nuclear cataracts and uveitis in HIV-transgenic mice. Eye 16:177-184
42. Ollo C, Johnson R, Grafman J (1991) Signs of cognitive change in HIV disease: an event-related brain potential study. Neurology 41:209-215
43. Pagano MA, Cahn PE, Garau ML, Mangone CA, Figini HA, Yorio AA, Dellepiane MC, Amores MG, Perez HM, Casiro AD (1992) Brain stem auditory evoked-potentials in human immunodeficiency virus-seropositive patients with and without acquired-immunodeficiency-syndrome. Arch Neurol 49:166-169
44. Peng JS, Vigorito M, Liu XQ, Zhou DJ, Wu XW, Chang SL (2010) The HIV-1 transgenic rat as a model for HIV-1 infected individuals on HAART. J Neuroimmunol 218:94-101
45. Phipps AJ, Hayes KA, Buck WR, Podell M, Mathes LE (2000) Neurophysiologic and immunologic abnormalities associated with feline immunodeficiency virus molecular clone FIV-PPR DNA inoculation. J Acquir Immune Defic Syndr 23:8-16
46. Prospero-Garcia O, Huitron-Resendiz S, Casalman SC, Sanchez-Alavez M, Diaz-Ruiz O, Navarro L, Lerner DL, Phillips TR, Elder JH, Henriksen SJ (1999) Feline immunodeficiency virus envelope protein (FIVgp120) causes electrophysiological alterations in rats. Brain Res 836:203-209
47. Purohit V, Rapaka R, Shurtleff D (2011) Drugs of abuse, dopamine, and HIV-1 associated neurocognitive disorders/HIV-associated dementia. Mol Neurobiol 44:102-110
48. Raymond LA, Wallace D, Berman NEJ, Marcario J, Foresman L, Joag SV, Raghavan R, Narayan O, Cheney PD (1998) Auditory brainstem responses in a Rhesus Macaque model of neuro-AIDS. J Neurovirol 4:512-520
49. Riazi M, Marcario JK, Samson FK, Kenjale H, Adany I, Staggs V, Ledford E, Marquis J, Narayan O, Cheney PD (2009) Rhesus macaque model of chronic opiate dependence and neuro-AIDS: longitudinal assessment of auditory brainstem responses and visual evoked potentials. J Neuroimmune Pharmacol 4:260-275
50. Royal W, Zhang L, Guo M, Jones O, Davis H, Bryant JL (2012) Immune activation, viral gene product expression and neurotoxicity in the HIV-1 transgenic rat. J Neuroimmunol 247:16-24
51. Rubel EW, Rosenthal MH (1975) Ontogeny of auditory frequency generalization in the chicken. J Exp Psychol Anim Behav Process 1:287-297
52. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136-142
53. Schroeder MM, Handelsman L, Torres L, Dorfman D, Rinaldi P, Jacobson J, Wiener J, Ritter W (1994) Early and late cognitive event-related potentials mark stages of HIV-1 infection in the drug-user risk group. Biol Psychiatry 35:54-69
54. Schroeder MM, Handelsman L, Torres L, Jacobson J, Ritter W (1996) Consistency of repeated event-related potentials in clinically stable HIV-infected drug users. J Neuropsychiatry Clin Neurosci 8:305-310
55. Silvers JM, Aksenova MV, Aksenov MY, Mactutus CF, Booze RM (2007) Neurotoxicity of HIV-1 tat protein: involvement of D1 dopamine receptor. Neurotoxicology 28:1184-1190
56. Tees RC (1976) Perceptual development in mammals. In: Gottlieb G (ed) Studies on the development of behavior and the nervous system: (Vol. 3), Neural and behavioral specificity. Academic, New York, pp 281-326
57. UNAIDS (2011) UNAIDS World AIDS Day Report 2011. http://www.unaids.org/ en/media/unaids/contentassets/documents/unaidspublication/2011/ JC2216-WorldAIDSday-report-2011-en.pdf
58. Vigliano P, Boffi P, Bonassi E, Gandione M, Marotta C, Raino E, Russo R, Rigardetto R (2000) Neurophysiologic exploration: a reliable tool in HIV-1 encephalopathy diagnosis in children. Panminerva Med 42:267-272
59. Wallace DR, Dodson S, Nath A, Booze RM (2006) Estrogen attenuates gp120-and tat(1-72)-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59:51-60
60. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, Ernst T, Fowler JS (2004) Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127:2452-2458
61. Werner H (1948) Comparative psychology of mental development. Follett, Chicago
62. Zhu J, Ananthan S, Mactutus CF, Booze RM (2011) Recombinant human immunodeficiency virus-1 transactivator of transcription(1-86) allosterically modulates dopamine transporter activity. Synapse 65:1251-1254
63. Zhu J, Mactutus CF, Wallace DR, Booze RM (2009) HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes. J Pharmacol Exp Ther 329:1071-1083